Bacardí R, Tornos J, Moga I, Martí N, Alomar P, Gaztelurrutia L, Villalonga C
Chemotherapy. 1977;23 Suppl 1:343-7. doi: 10.1159/000222074.
Results are presented for a series of 29 patients, 14 males and 15 females, with serious respiratory infections, in which fosfomycin proved effective. In all cases the study was completed by bacteriological, clinical, radiological and analytical controls. The average dose was 6 g/day (3 g orally and 3 g intramuscularly) for 1 or 2 weeks. The four isolated were P. aeruginosa, E. coli, Klebsiella-Enterobacter and D. pneumoniae. Overall sensitivity percentages were best for fosfomycin, gentamicin and colistin. Of the 29 germs isolated, only one strain of P. aeruginosa became resistant: this represents 3% resistance development. No side effects of intolerance or signs of hepatorenal insufficiency were observed during the treatment. Of the 29 patients treated, 22 were clinically cured, denoting 76% success.
结果呈现了29例患有严重呼吸道感染的患者(14名男性和15名女性)使用磷霉素有效的情况。在所有病例中,该研究均通过细菌学、临床、放射学和分析对照得以完成。平均剂量为6克/天(口服3克,肌肉注射3克),持续1或2周。分离出的四种病菌为铜绿假单胞菌、大肠杆菌、克雷伯菌-肠杆菌和肺炎双球菌。总体敏感性百分比对磷霉素、庆大霉素和黏菌素而言最佳。在分离出的29种病菌中,仅一株铜绿假单胞菌产生了耐药性:这代表耐药性发展率为3%。治疗期间未观察到不耐受的副作用或肝肾不足的迹象。在接受治疗的29例患者中,22例临床治愈,成功率为76%。